“This is meant to provide that foundational knowledge for people so that they can understand all the interdisciplinary work that’s been done about psychedelics.” “Usually, the only message that’s been out there is, ‘drugs are bad, drugs are dangerous, don’t do drugs,’” Davis said. He added that educating professionals with social work degrees is essential because they are the biggest part of the workforce dealing directly with patients in a clinical setting. ![]() Other universities are also studying the therapeutic value of psilocybin and other psychedelics, but Davis says Ohio State is the first to create such a center in a social work setting. “With some studies, they’ve seen that those positive effects can last six to 12 months.” The ongoing research suggests that treatment with psychedelics such as psilocybin, when combined with psychotherapy, can “reduce and, for some, ameliorate, the mental health problems that they are dealing with,” Davis said. “All of those studies so far have shown really promising effects.” “Currently, there have been clinical trials completed for people with addiction, depression, PTSD, obsessive-compulsive disorder, social anxiety end-of-life distress in patients who are terminally ill,” Davis told Columbus Monthly earlier this year. In January, the center launched its first clinical trial to explore the use of psilocybin as a treatment for military veterans diagnosed with PTSD. The center has developed a 25-hour continuing education program and an undergraduate minor in psychedelic studies. The following year, the FDA granted the same status to psilocybin as a breakthrough therapy for treatment-resistant depression.Īlan Davis serves as the director of the Center for Psychedelic Drug Research and Education in the College of Social Work at Ohio State University, which he launched last year with the assistance of a private donation of $1.5 million. Food and Drug Administration designated MDMA as a breakthrough therapy for PTSD, a move that streamlined clinical trials to test the effectiveness of the drug. Separate research published in 2016 determined that psilocybin treatment produced substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. A study published in the peer-reviewed journal JAMA Psychiatry in 2020 found that psilocybin-assisted psychotherapy was an effective and quick-acting treatment for a group of 24 participants with major depressive disorder. Walsh said that it is possible that psilocybin mushrooms “have multi-dimensional healing properties” that could more effectively improve the quality of life for people with severe mental illness.Ĭontinuing research into psychedelics including psilocybin, MDMA and ketamine has shown that the drugs have potential therapeutic benefits, particularly for serious mental health conditions such as depression, addiction and anxiety. Researchers believe that using whole mushrooms in mental health studies could give participants the advantage of other compounds besides psilocybin, potentially offering additional therapeutic benefits. “By combining cutting-edge techniques in genomics and metabolomics, we have the opportunity to obtain a high-resolution picture of the chemical diversity of mushrooms that have remained difficult to study for several decades,” said Ohio State researchers Dr. Under the terms of the license, all cultivation of psilocybin mushrooms will take place in a federally registered facility in accordance with strict DEA regulations. The new license issued by the DEA allows Ohio State and Inner State to grow whole psilocybin mushrooms to produce the compound naturally. But studies of psilocybin normally use forms of the drug that have been synthesized in a laboratory. Multiple studies have shown that psilocybin, the primary psychoactive compound in magic mushrooms, may have extraordinary potential as a treatment for several serious mental health conditions. ![]() “This license is a major milestone not only for Inner State and Ohio State, but for the entire field of psychedelic research,” Inner State CEO Ashley Walsh said on Wednesday in a statement quoted by the Columbus Dispatch. The license, which was awarded to Ohio State and partner Inner State Inc., a mental health and wellness research and development company, is the first license issued by the DEA for the cultivation of whole psilocybin mushrooms for research. Drug Enforcement Administration has issued a license to Ohio State University that allows researchers to cultivate psilocybin mushrooms for use in scientific studies.
0 Comments
Leave a Reply. |